NCT06670898View on ClinicalTrials.gov

A Study of Absorption, Metabolism, Excretion of [14C]-NS-580 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions
Healthy
Interventions
DRUG

[14C] NS-580

Oral suspension

Trial Locations (1)

LS11 9EH

Fortrea Clinical Research Unit Ltd, Leeds

Sponsors
All Listed Sponsors
lead

Nippon Shinyaku Co., Ltd.

INDUSTRY